Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The ONKOTEV score predicts the risk of venous thromboembolism in cancer patients.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
Hidradenitis Suppurativa in 2025: Year in Review
1.
Global inequalities found in cancer research funding
2.
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen
3.
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
4.
Congresswoman has cancer; the IRS is suing a controversial doctor; and caffeine and teenagers.
5.
Advanced breast cancer patients living longer thanks to improvements in treatment and care
1.
The Importance of Having a Quick and Effective Heparin Antidote
2.
Botulinum Toxins in Oncology: A New Frontier in Chronic Pain Management and Apoptosis Induction
3.
Does Lactate Signal Anemia? Exploring the Complexities of Hyperlactatemia and Red Blood Cell Health
4.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
5.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge